NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Biodesix, Inc. (BDSX) Stock Analysis

Biodesix, Inc. (BDSX) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

BDSX

$26.18

−$0.30 (−1.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BDSX with… →

BDSX Key Statistics

As of Sep 4, 2026
Trading
Open
$26.23
Previous Close
$26.48
Day's Range
25.42–26.76
52-Week Range
5.26–31.31
Volume
58.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.59
Valuation
Market Cap
$276.23M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.68
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.07
Financials (FY)
Revenue (FY)
$88.50M+24.08%
Net Income (FY)
−$35.27M
Profit marginThe share of revenue left as profit after all costs and taxes.
−26.97%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.55M
1-Year Return
+195.49%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
97.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BDSX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+285.00%
2025−77.78%
2024−16.85%
2023−20.00%
2022−56.52%
2021−73.76%
2020 (partial year)+57.38%

As of September 4, 2026.

BDSX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$88.50M−$35.27M−39.8%
2024$71.32M−$42.93M−60.2%
2023$49.09M−$52.15M−106.2%
2022$38.21M−$65.45M−171.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$88.50M$71.78M−$27.77M−$35.27M−39.8%
2024$71.32M$55.75M−$34.26M−$42.93M−60.2%
2023$49.09M$36.08M−$41.30M−$52.15M−106.2%
2022$38.21M$24.06M−$50.51M−$65.45M−171.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BDSX Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricBDSXDiagnostics & Research medianvs median
P/S ratio2.684.9946% below
Profit margin−26.97%0.00%27.0 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Biodesix, Inc. (BDSX) at $276.23M. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 334 employees.

The most recent close on file for BDSX is $26.18, dated September 4, 2026. That is −$0.30 (−1.11%) against the previous close. Over the past 52 weeks the price has ranged from $5.26 to $31.31. The latest close sits 397.72% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $88.50M. Against the prior fiscal year total of $71.32M, that is a change of +24.08%. The same year closed with a net loss of $35.27M. Profit margin runs at −26.97%. That is 27 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −3.07.

Across the 4 fiscal years on file, revenue moves from $38.21M in 2022 to $88.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.68 times revenue. On price-to-sales that is 46.23% below the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 0.59. Daily returns over the trailing 5 years annualize to a volatility of 102.53%. The trailing one-year price return is +195.49%. Across 5 years the annualized return works out at −32.81%.

Growth & Income

The record shows no dividend for BDSX.

The strongest complete calendar year on file is 2024 at −16.85%; the weakest is 2025 at −77.78%. Of the 5 complete calendar years on file, 0 finished higher. So far in 2026 the price is +285.00%.

Peer Comparison

Biodesix, Inc. (BDSX) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biodesix, Inc. BDSX $276.23M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Biodesix, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Biodesix, Inc.

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Visit website →